Extending the Benefit of Antibody-Drug Conjugates in Breast Cancer Treatment: A New Strategy for Overcoming Resistance
Published: December 14, 2025
Introduction:
Recent research from the University of Hawaiʻi Cancer Center offers a promising new approach to extending the effectiveness of antibody-drug conjugates (ADCs) in the treatment of breast cancer. Presented at the San Antonio Breast Cancer Symposium on December 10, 2025, the study suggests that strategically switching ADC types – specifically, utilizing different drug classes – can restore treatment sensitivity in tumors that have developed resistance to an initial ADC therapy. This revelation provides a crucial insight into overcoming drug resistance and maximizing the potential of these targeted cancer treatments.
Understanding antibody-Drug Conjugates (ADCs)
Antibody-drug conjugates represent a sophisticated advancement in cancer therapy. These treatments combine the precision of antibodies – proteins designed to recognize and bind to specific targets on cancer cells – with the potency of cytotoxic
Keep reading